Abstract:
The present invention provides a lubricating composition comprising: (a) an oil of lubricating viscosity; and (b) a crosslinked polymer derived from monomers comprising: (i) 0.001 wt % to 7 wt % of a di- or higher functional crosslinking monomer; (ii) 30 wt % or higher of a hydrocarbyl-substituted (meth)acrylic monomer, wherein each hydrocarbyl contains greater than 8 carbon atoms; and (iii) 0 wt % to 40 wt % of a hydrocarbyl-substituted (meth)acrylic monomer, wherein each hydrocarbyl contains 8 or fewer carbon atoms. The invention further provides a method of preparing the crosslinked polymer and its use in a lubricating composition for lubricating an internal combustion engine.
Abstract:
The invention provides a system and method for controlling use of handset communication device for communication by driver. A system in accordance with an embodiment includes: an obtaining component for obtaining driving state information of the vehicle; a directional antenna for capturing a wireless communication signal of the handset communication device around the driver; a judging component for judging whether a driving state of the vehicle is in an unstable state based on predefined criteria and the driving state information of the vehicle; and a control component for transmitting a remote control signal, based on a judging result of the judging component, to intervene in a communication of the handset communication device during a call.
Abstract:
Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.
Abstract:
The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.
Abstract:
The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
Abstract:
The present application provides for various embodiments of methods for the analysis of high resolution melt (HRM) curve data; where statistical assay variations in melt curve data may result from system noise in an analysis system. Such system noise may arise from various sources, such as the thermal non-uniformity of a thermocycler block in a thermal cycler apparatus, a detection system, etc. Additionally, various methods for the analysis of HRM curve data may provide an identification of a sample without the need for a user inputted information.
Abstract:
A method, system, and article of manufacture for defining and managing time-based organization hierarchies are disclosed herein. In one embodiment, a user interface, including a plurality of user interface displays configured to receive a user input to define and/or manage one or more instances of a time-based organization hierarchy, may be generated on a client. The user may then define, via interaction with the user interface, the at least one instance of the organization hierarchy to include a plurality of nodes, and specify an effective period for the instance of the time-based organization hierarchy by defining a start date and an end date. The user may also define a territory to correspond to each of the plurality of nodes in the organization hierarchy. In one embodiment, the territory may include at least one position and an assignment rule, the position having a corresponding quota.
Abstract:
A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.
Abstract:
The present invention is drawn to diagnosis and treatment of essential hypertension. In this regard, the present invention discloses genetic variants in a hypertension susceptibility gene Stk39 and its use in the diagnosis and treatment of essential hypertension.
Abstract:
The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2 -a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7 -octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2 -a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.